Mahlknecht Ulrich, Voelter-Mahlknecht Susanne
University of Heidelberg Medical Center, Department of Hematology/Oncology, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
Curr Med Res Opin. 2005 Jul;21(7):1041-7. doi: 10.1185/030079905X50633.
The progressively aging population in the western world, rising socioeconomic expenditure and increasing costs for the treatment of adverse drug reactions, lead to increasing pressure on public spending. The public acceptance of pharmacogenomics is high, therefore, because it promises individualized safe and effective treatment at lower cost. Pharmacogenomics studies the genetic polymorphisms that underlie the variability in drug response between individuals. Despite the great benefits being awaited from this new field, a number of ethical, social and legal concerns arise, which demand rapid strict international regulations in order to prevent discrimination or harm of any kind from society, industry, groups or individuals.
西方世界人口老龄化的加剧、社会经济支出的增加以及药物不良反应治疗成本的上升，导致公共支出压力不断增大。因此，药物基因组学受到公众的高度认可，因为它有望以更低的成本实现个性化的安全有效治疗。药物基因组学研究个体间药物反应差异背后的基因多态性。尽管人们期待这个新领域能带来巨大益处，但也出现了一些伦理、社会和法律问题，这就需要迅速制定严格的国际法规，以防止来自社会、行业、团体或个人的任何形式的歧视或伤害。
